Profile picture

Professor Kausik K Ray

Imperial College London, London (United Kingdom of Great Britain & Northern Ireland)
Membership: FESC Member
Follow
Biography
Kausik Ray FESC is Professor of Public Heath, Director of the Imperial Centre for CVD Prevention, Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials Imperial College London and Consultant Cardiologist. He received his medical education Birmingham Univ, MD from Sheffield Univ, a fellowship at Harvard Medical School and finally an MPhil in Epidemiology at Cambridge Univ. He is current president of the EAS and national CVD prevention lead for the NIHR ARC. Professor Ray: is the lead for the 70 country FH Studies Collaboration the only global registry of FH, PI for the TOGETHER study looking at cardiometabolic risk in the vascular health checks in 250,000 people in London. Professor Ray has led and participated in several novel therapies for hypercholesterolaemia and diabetes. Voted by Clarivate as among the top 1% of authors cited in clinical medicine globally H Index 84, i10 218 and ~ 90,000 citations.
Logo ESC

Contributor content

Cardiovascular risk management of high-risk patients with dyslipidaemia: innovative approaches from assessment to combination therapy
Session
Cardiovascular risk management of high-risk patients with dyslipidaemia: innovative approaches from assessment to combination therapy
30 August 2025
Ask the Trialists - VICTORION
Session
Ask the Trialists - VICTORION
30 August 2025
Obesity and systemic metabolic disorders: burden, staging, and management
Session
Obesity and systemic metabolic disorders: burden, staging, and management
29 August 2025
Lp(a) in cardiovascular disease: current insights and future therapies
Session
Lp(a) in cardiovascular disease: current insights and future therapies
29 August 2025
Clinical choices in managing LDL-c: where do novel therapies fit in?
Session
Clinical choices in managing LDL-c: where do novel therapies fit in?
1 September 2024
Sustained LDL-C reduction: from long-term trials to real-world implementation
Session
Sustained LDL-C reduction: from long-term trials to real-world implementation
1 September 2024
Registries, observational, and other studies on lipids
Session
Registries, observational, and other studies on lipids
1 September 2024
Innovating the clinical management of LDL-c: exploring CETP as therapeutic target
Session
Innovating the clinical management of LDL-c: exploring CETP as therapeutic target
30 August 2024
Targeting the spectrum of atherogenic lipoproteins: what to do and how to do it
Session
Targeting the spectrum of atherogenic lipoproteins: what to do and how to do it
25 August 2023
The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management
Session
The LDL-c challenge in patients with high cardiovascular risk: integrating innovative therapies in clinical management
25 August 2023

ESC 365 is supported by